Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (3) ·
3-MMC (1) ·
7-Hydroxymitragynine (1) ·
Acacia confusa (1) ·
Amanita muscaria (1) ·
Ayahuasca (1) ·
Blue lotus (1) ·
Butylone (1) ·
Calea zacatechichi (1) ·
Cathinone (1) ·
Datura (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Harmaline (1) ·
Harmine (1) ·
Hawaiian Baby Woodrose (1) ·
Hexedrone (1) ·
Iboga (1) ·
Kava (1) ·
Kratom (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
Mitragynine (1) ·
Morning Glory (1) ·
Myristicin (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Pentedrone (1) ·
Peyote (1) ·
Psilocybin mushrooms (1) ·
Salvia divinorum (1) ·
San Pedro cactus (1) ·
Syrian rue (1) ·
Tetrahydroharmine (1) ·
Yopo (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Apomorphine and nuciferine; dopaminergic activity (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Contains atropine, scopolamine, hyoscyamine (1) ·
Contains bufotenin and DMT (1) ·
Contains harmine, harmaline, tetrahydroharmine (1) ·
Contains ibogaine; kappa-opioid agonist (1) ·
Contains LSA (2) ·
Contains mescaline (2) ·
Contains muscimol and ibotenic acid (1) ·
Contains psilocybin and psilocin (1) ·
Contains salvinorin A (1) ·
DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) ·
DMT-containing plant used in psychedelic preparations (1) ·
Kavalactones; GABAA modulator; sigma receptor activity (1) ·
Mechanism incompletely understood (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Partial MAOI; anticholinergic effects (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Potent mu-opioid receptor agonist (1) ·
Reversible MAO-A inhibitor; beta-carboline (1) ·
Reversible MAO-A inhibitor; NMDA antagonist; beta-carboline (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Weak serotonin reuptake inhibitor; beta-carboline (1)
uses:
None (37) ·
Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). (1)
starting dose:
None (37) ·
42 mg PO once daily with food (no titration) (1) ·
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) ·
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 40 results in range #1 to #40.